Anti-MEK1 (phospho T286) antibody [EP2364Y] (ab68140)

Overview

  • Product name
    Anti-MEK1 (phospho T286) antibody [EP2364Y]
    See all MEK1 primary antibodies
  • Description
    Rabbit monoclonal [EP2364Y] to MEK1 (phospho T286)
  • Specificity
    This antibody detects MEK1 phosphorylated at threonine 286.
  • Tested applications
    Suitable for: WB, IPmore details
    Unsuitable for: Flow Cyt,ICC or IHC-P
  • Species reactivity
    Reacts with: Human
  • Immunogen

    A phospho-specific peptide corresponding to residues surrounding threonine 286 of human MEK1

  • Positive control
    • A431 cell lysate
  • General notes

    A trial size is available to purchase for this antibody.

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab68140 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
IP
  • Application notes
    IP: 1/50.
    WB: 1/2000. Predicted molecular weight: 43 kDa.

    Is unsuitable for Flow Cyt, ICC or IHC-P.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Catalyzes the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in MAP kinases. Activates ERK1 and ERK2 MAP kinases.
    • Tissue specificity
      Widely expressed, with extremely low levels in brain.
    • Involvement in disease
      Defects in MAP2K1 are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
    • Sequence similarities
      Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.
      Contains 1 protein kinase domain.
    • Post-translational
      modifications
      Phosphorylation on Ser/Thr by MAP kinase kinase kinases (RAF or MEKK1) regulates positively the kinase activity.
      Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.
    • Information by UniProt
    • Database links
    • Alternative names
      • Dual specificity mitogen activated protein kinase kinase 1 antibody
      • Dual specificity mitogen-activated protein kinase kinase 1 antibody
      • ERK activator kinase 1 antibody
      • MAP kinase kinase 1 antibody
      • MAP kinase/Erk kinase 1 antibody
      • MAP2K1 antibody
      • MAPK/ERK kinase 1 antibody
      • MAPKK 1 antibody
      • MAPKK1 antibody
      • MEK 1 antibody
      • Mek1 antibody
      • MEKK1 antibody
      • Mitogen activated protein kinase kinase 1 antibody
      • MKK 1 antibody
      • MKK1 antibody
      • MP2K1_HUMAN antibody
      • PRKMK1 antibody
      • Protein kinase mitogen activated kinase 1 (MAP kinase kinase 1) antibody
      • Protein kinase mitogen activated, kinase 1 antibody
      see all

    Images

    • All lanes : Anti-MEK1 (phospho T286) antibody [EP2364Y] (ab68140) at 1/2000 dilution

      Lane 1 : A431 cell lysate, untreated
      Lane 2 : A431 cell lysate, treated with nocodazole

      Lysates/proteins at 10 µg per lane.

      Secondary
      HRP-labeled goat anti-rabbit at 1/2000 dilution

      Predicted band size : 43 kDa
      Observed band size : 43 kDa

    References

    ab68140 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab68140.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up